Summit Therapeutics Stock News

Cambridge, MA, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) today announced topline results for the Phase III Ri-CoDIFy study evaluat

The company just revealed disappointing phase 3 trial results for its only clinical-stage drug candidate.

Wall Street analysts forecast that Summit Therapeutics Inc. (NASDAQ:SMMT) will post earnings of ($0.27) per share for the current quarter, Zacks reports. Zero analysts have provided estimates for Summit Therapeutics earnings. Summit Therapeutics reported earnings of ($0.18) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 50%. The []

Summit Therapeutics (NASDAQ:SMMT) and Myovant Sciences (NYSE:MYOV) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability. Profitability This table compares Summit Therapeutics and Myovant Sciences net margins, return on equity and []

Summit Therapeutics Inc. (NASDAQ:SMMT) was the recipient of some unusual options trading on Thursday. Traders bought 2,608 call options on the stock. This is an increase of approximately 2,360% compared to the typical daily volume of 106 call options. Several equities analysts have issued reports on SMMT shares. Zacks Investment Research raised Summit Therapeutics from []

HC Wainwright restated their hold rating on shares of Summit Therapeutics (NASDAQ:SMMT) in a research note issued to investors on Monday, Price Targets.com reports. Separately, Zacks Investment Research raised shares of Summit Therapeutics from a strong sell rating to a hold rating in a research report on Thursday, October 14th. Shares of SMMT stock opened []

Northern Trust Corp acquired a new stake in Summit Therapeutics Inc. (NASDAQ:SMMT) in the 2nd quarter, Holdings Channel reports. The firm acquired 34,255 shares of the companys stock, valued at approximately $256,000. Other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in Summit Therapeutics []

Wall Street analysts forecast that Summit Therapeutics Inc. (NASDAQ:SMMT) will report earnings of ($0.28) per share for the current quarter, according to Zacks. Zero analysts have issued estimates for Summit Therapeutics earnings. Summit Therapeutics posted earnings of ($0.18) per share in the same quarter last year, which would suggest a negative year over year growth []

Summit Therapeutics (NASDAQ:SMMT) announced its earnings results on Monday. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.09, MarketWatch Earnings reports. Summit Therapeutics had a negative return on equity of 96.34% and a negative net margin of 350.72%. SMMT stock opened at $5.41 on Thursday. []

Summit Therapeutics Inc. (NASDAQ:SMMT) shares passed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $5.48 and traded as low as $5.15. Summit Therapeutics shares last traded at $5.20, with a volume of 84,598 shares traded. Separately, Zacks Investment Research upgraded Summit Therapeutics from a strong []

Cambridge, Massachusetts, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on

Cambridge, MA, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that Kenneth A. Clark, JD, has been appointed to our Board of Directors, effective immediately

SAN DIEGO, Oct. 2, 2021 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of the federal securities laws by Summit Therapeutics Inc. ("Summit" or th

New York, New York--(Newsfile Corp. - October 1, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ: SMMT). Such inves